Company intelligence / Profile preview

Bio Preventive Medicine

Zhubei, Hsinchu, Taiwantw.bpmbiotech.com ↗

Ownership: Private
Development stage: Commercial

Overview

Bio Preventive Medicine has developed and commercialized DNlite, a molecular diagnostic test for early detection of diabetic nephropathy. The company focuses on innovative biomarker-based diagnostics to enable preventive medicine, with products available in the market and global patent coverage[1][5][7].

Therapeutic areas: Metabolic DisordersNephrology
Modalities: Diagnostic test
Industry: Molecular Diagnostics

Drug pipeline

1 asset

DNlite-IVD103

Commercial

Indications: Diabetic kidney disease, Kidney transplant monitoring

Partnerships

Not publicly disclosed; focus is on product development and commercialization.

Beyond the preview

Go deeper on Bio Preventive Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio Preventive Medicine.

Explore the full profile